Pharmacogenomic Screening helps GPs reduce prescribing uncertainty in patients with side effects, limited response, or complex medication histories. You receive a structured PGx report with actionable guidance in 2–3 weeks.
If any of these apply, the report is more likely to change or sharpen your next prescribing decision.
The patient has had limited benefit from two or more adequate medication trials. PGx may help explain whether metabolism or gene–drug effects are contributing.
The patient reports unusually severe or atypical adverse effects at standard doses. Poor or ultrarapid metaboliser status can help explain the pattern.
The patient is taking multiple medications with overlapping CYP pathways. PGx can support safer combination prescribing and flag likely interaction pressure points.
You are about to start or switch an antidepressant, antipsychotic, mood stabiliser, or other medication with useful PGx evidence behind it.
The patient wants a more informed discussion before committing to another medication pathway. The result is durable and can inform future prescribing.
First-degree relatives with documented adverse drug reactions or treatment resistance. Pharmacogenomic variants are heritable and family history is clinically relevant.
The value is not just the gene data. It is getting a report back that helps you make a more confident medication decision.
Choose medications and doses with a better understanding of how the patient is likely to metabolise and respond, rather than relying on population averages alone.
Identify patients at elevated risk of adverse effects from standard doses before initiating treatment, particularly for psychiatric and pain medications.
A simple cheek swab collected at home, with no clinic visit and no blood draw. The kit is mailed to your patient and returned by prepaid post.
Results are interpreted against CPIC, DPWG, and PharmGKB evidence tiers so the output is clinically anchored rather than consumer-style genetics reporting.
You receive a structured clinical report with metaboliser status, interaction flags, and plain-language prescribing guidance for relevant drug classes.
The TBMH-PGx team is available to assist with report interpretation and to discuss prescribing implications for complex cases.
The TBMH-PGx quick reference guide shows that the current panel extends well beyond a narrow psychiatry-only use case. It maps 74+ medications across psychiatry, neurology, pain management, and selected general medicine prescribing, helping referrers judge when testing is likely to produce actionable information.
The deepest coverage area in the panel, spanning antidepressants, antipsychotics, anxiolytics, stimulants, and mood stabilisers.
Representative coverage: Aripiprazole, risperidone, escitalopram, sertraline, venlafaxine, nortriptyline, bupropion, mirtazapine, dexamphetamine, lisdexamfetamine, lithium, carbamazepine, lamotrigine, and sodium valproate.
Common genes: Key genes include CYP2D6, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CES1, HLA-A, HLA-B, UGT1A4, UGT1A6, and POLG.
Useful for clinicians managing cognition, seizure disorders, sleep-wake prescribing, and movement-related therapy.
Representative coverage: Donepezil, galantamine, phenytoin, primidone, phenobarbital, modafinil, and tetrabenazine.
Common genes: Most frequently implicated genes are CYP2D6, CYP2C19, CYP2C9, and CYP3A4.
Captures several high-impact analgesic pathways where under-response and toxicity risk are both clinically relevant.
Representative coverage: Codeine, tramadol, oxycodone, fentanyl, methadone, morphine, celecoxib, ibuprofen, and ketamine/esketamine.
Common genes: Common drivers include CYP2D6, CYP3A4, CYP2B6, CYP2C9, ABCB1, and UGT2B7.
Smaller in scope, but relevant where psychiatric care intersects with sleep, cardiovascular, and behavioural prescribing.
Representative coverage: Melatonin, propranolol, and guanfacine.
Common genes: Coverage includes CYP1A2, CYP2C19, CYP2D6, and CYP3A4.
The quick-reference guide ranks these genes by the number of medications they influence within the panel.
Broadest influence across antidepressants, antipsychotics, stimulants, opioids, and tetrabenazine.
High relevance for antipsychotics, anxiolytics, ketamine/esketamine, donepezil, and several analgesics.
Prominent in SSRIs, TCAs, diazepam, modafinil, and selected anticonvulsants.
Important for NSAIDs, phenytoin, phenobarbital, primidone, and valproate-related interpretation.
Frequently relevant for clozapine, olanzapine, duloxetine, melatonin, and propranolol.
Key for bupropion, methadone, tramadol, sertraline, and ketamine/esketamine metabolism.
The referral workflow is designed to be operationally light for the GP. You refer, the patient completes the home-kit and payment steps, and the report returns to you.
The form only asks for the details needed to start the patient workflow.
TBMH manages payment instructions, kit dispatch, and patient-facing logistics after referral.
The final output is delivered to the referring clinician for prescribing review and follow-up.
Enter your details and the patient's information, including medications under consideration
An email is sent directly to your patient with referral details and instructions to purchase their test kit
The patient purchases and receives a cheek swab kit by mail, returns it using prepaid packaging, all from home
The sample is processed at an Australian NATA-accredited laboratory within 10–14 business days
The structured PGx report is emailed directly to you, ready for clinical interpretation and prescribing decisions
Complete the form below. The referral will be securely packaged for TBMH's private intake worker. The patient will receive payment instructions after the private system imports the referral.
Please review the details below. When you click "Submit Referral", the referral will be encrypted and sent to TBMH's private intake workflow.
TBMH's private intake workflow will validate the referral and send payment instructions to:
GPs typically want three things back: a fast summary, clear metaboliser findings, and practical prescribing guidance. The report is designed around that need.
Referral details, patient demographics, and a one-page executive summary of key findings for rapid clinical review.
CYP2D6, CYP2C19, CYP2C9, CYP3A4/5, and other relevant enzymes, each assigned a metaboliser phenotype (Poor, Intermediate, Normal, Rapid, or Ultrarapid).
Traffic-light coding (use with caution, consider alternatives, standard use) for all clinically relevant medications in the CPIC/DPWG evidence database.
Plain-language clinical recommendations for antidepressants, antipsychotics, analgesics, anticoagulants, and other drug classes, cross-referenced to CPIC guidelines.
Full star-allele assignments and diplotype data, available for specialist review or if results are later re-analysed against updated guidelines.
The TBMH-PGx Essential Panel covers the genes with the strongest clinical evidence for psychiatric and pain medication management:
Evidence-based resources for healthcare professionals integrating pharmacogenomics into clinical practice.
Comprehensive overview of medical genetics principles relevant to pharmacogenomics implementation.
Royal College of Pathologists of Australasia guidance on PGx indications and implementation for Australian clinicians.
Peer-reviewed, evidence-based guidelines for translating genetic test results into actionable prescribing decisions.
Curated database of gene-drug relationships, variant annotations, and pathway information.
Australian Genomics research priorities and implementation guidance for pharmacogenomics in the Australian healthcare system.
Australian Institute for Health and Welfare data on medicines use in Australia, contextualising the scale of PGx relevance.